Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Risk and Volatility
Oramed Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Insider & Institutional Ownership
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oramed Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
ProKidney has a consensus price target of $10.00, indicating a potential upside of 866.18%. Given ProKidney’s higher probable upside, analysts plainly believe ProKidney is more favorable than Oramed Pharmaceuticals.
Profitability
This table compares Oramed Pharmaceuticals and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oramed Pharmaceuticals | N/A | -7.57% | -6.58% |
| ProKidney | -13,326.71% | N/A | -37.98% |
Valuation and Earnings
This table compares Oramed Pharmaceuticals and ProKidney”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oramed Pharmaceuticals | $2.00 million | 80.81 | $64.05 million | $6.16 | 0.63 |
| ProKidney | $818,000.00 | 382.52 | -$68.99 million | ($0.60) | -1.72 |
Oramed Pharmaceuticals has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ProKidney beats Oramed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.
About ProKidney
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
